Prelude Therapeutics to Join Citizens JMP Life Sciences 2024 Conference

WILMINGTON, Del., May 09, 2024 – Prelude Therapeutics Incorporated, a company in the clinical-stage of precision oncology, announced its participation in the Citizens JMP Life Sciences Conference in New York City on May 13 and 14. On May 14 at 1:00 p.m. ET, the company's Chief Executive Officer, Kris Vaddi, Ph.D., and the President and Chief Medical Officer, Jane Huang, M.D., will engage in a fireside chat. This event will be available via live webcast on the company's website, with an archived recording accessible for 90 days.

Prelude Therapeutics focuses on the development of innovative drug candidates targeting key cancer cell pathways. The company’s pipeline features several highly differentiated small molecule compounds that are potentially best-in-class. These drug candidates are designed to address clinically validated pathways in cancers affecting underserved patients. Currently, the company has three candidates in clinical development: PRT3789, PRT2527, and PRT3645.

PRT3789 stands out as a potent, highly selective SMARCA2 degrader administered through IV. PRT2527 is a selective inhibitor of CDK9, while PRT3645 represents the next generation of CDK4/6 inhibitors. Additionally, Prelude is advancing PRT7732, an orally bioavailable SMARCA2 degrader with high selectivity.

In collaboration with AbCellera, Prelude is working to create up to five precision, next-generation antibody-drug conjugate (ADC) products. This partnership combines AbCellera’s expertise in antibody discovery and development with Prelude’s skills in medicinal chemistry and drug development.

Prelude Therapeutics remains dedicated to pioneering the development of novel therapeutic options for patients with cancer, focusing on precision oncology to improve patient outcomes.